DGIdb - NINTEDANIB Drug Record

NINTEDANIB chembl:CHEMBL502835 ApprovedAntineoplastic

Alternate Names:

VARGATEF
BIBF1120
NINTEDANIB
OFEV
BIBF-1120
INTEDANIB
METHYL (3Z)-3-[(4-{METHYL[(4-METHYLPIPERAZIN-1-YL)ACETYL]AMINO}ANILINO)(PHENYL)METHYLIDENE]-2-OXO-2,3-DIHYDRO-1H-INDOLE-6-CARBOXYLATE
OFEV®
VARGATEF®
BIBF 1120
drugbank:09079
chembl:CHEMBL502835
chemidplus:656247-17-5
rxcui:1592737
pubchem.compound:9809715

Drug Info:

Drug Class	Kinase Inhibitors
FDA Approval	not approved
Drug Class	Small molecule
Drug Indications	antineoplastic agent

(4 More Sources)

Publications:

Hilberg et al., 2008, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy., Cancer Res.
Wind S et al., 2019, Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib., Clin Pharmacokinet
Gozgit et al., 2012, Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models., Mol. Cancer Ther.
Roth GJ et al., 2009, Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120)., J Med Chem

NINTEDANIB FGR

Interaction Score: 0.49

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
None found

Sources:
TALC
NINTEDANIB FGFR2

Interaction Score: 0.46

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name BIBF-1120,Vargatef

Novel drug target Established target

Notes

PMIDs:
18559524 22238366 31016670

Sources:
TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial JAX-CKB
NINTEDANIB CFLAR

Interaction Score: 0.42

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
ClearityFoundationClinicalTrial
NINTEDANIB FGFR3

Interaction Score: 0.38

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Response Type resistant

Indication/Tumor Type urinary bladder cancer

Evidence Type Actionable

PMIDs:
22238366 18559524 31016670

Sources:
TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial JAX-CKB
NINTEDANIB FGFR1

Interaction Score: 0.31

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Indication/Tumor Type Advanced Solid Tumor

Response Type decreased response

PMIDs:
18559524 22238366 31016670

Sources:
TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial JAX-CKB TTD
NINTEDANIB PDGFRA

Interaction Score: 0.28

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Trial Name BIBF-1120,Vargatef

Novel drug target Established target

PMIDs:
31016670 18559524

Sources:
TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial
NINTEDANIB PDGFRB

Interaction Score: 0.25

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Trial Name BIBF-1120,Vargatef

Novel drug target Established target

PMIDs:
31016670 18559524

Sources:
TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial
NINTEDANIB FLT1

Interaction Score: 0.22

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Trial Name BIBF-1120,Vargatef

Novel drug target Established target

PMIDs:
18559524 31016670

Sources:
TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial
NINTEDANIB LYN

Interaction Score: 0.22

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
18559524 31016670

Sources:
TALC
NINTEDANIB FLT4

Interaction Score: 0.21

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name BIBF-1120,Vargatef

Novel drug target Established target

Notes

PMIDs:
18559524 31016670

Sources:
TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial
NINTEDANIB KDR

Interaction Score: 0.19

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name BIBF-1120,Vargatef

Notes

PMIDs:
18559524 19522465 31016670

Sources:
TALC DTC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial
NINTEDANIB LCK

Interaction Score: 0.17

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
18559524 31016670

Sources:
TALC
NINTEDANIB HCK

Interaction Score: 0.16

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
None found

Sources:
TALC
NINTEDANIB SRC

Interaction Score: 0.16

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
18559524 31016670

Sources:
TALC
NINTEDANIB FGFR4

Interaction Score: 0.11

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
ClearityFoundationClinicalTrial
NINTEDANIB FRK

Interaction Score: 0.11

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
None found

Sources:
TALC
NINTEDANIB FLT3

Interaction Score: 0.1

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
18559524 31016670

Sources:
TTD
NINTEDANIB FYN

Interaction Score: 0.09

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
None found

Sources:
TALC
NINTEDANIB BLK

Interaction Score: 0.09

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
None found

Sources:
TALC
NINTEDANIB AKT1

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18559524

Sources:
DTC
NINTEDANIB YES1

Interaction Score: 0.01

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
None found

Sources:
TALC

MyCancerGenome: NINTEDANIB
- Version: 20-Jun-2017
Alternate Names:

BIBF1120 Development Name

NINTEDANIB Generic Name

VARGATEF Trade Name

Drug Info:

Drug Class Kinase Inhibitors

Publications:
TdgClinicalTrial: NINTEDANIB
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small molecule

FDA Approval not approved

Publications:

DTC: NINTEDANIB

Version: 02-September-2020

Alternate Names:

CHEMBL502835 ChEMBL Drug ID

Drug Info:

Publications:

Hilberg et al., 2008, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy., Cancer Res.

Roth GJ et al., 2009, Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120)., J Med Chem

JAX-CKB: Nintedanib
- Version: 27-September-2017
Alternate Names:

Drug Info:

Publications:

Gozgit et al., 2012, Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models., Mol. Cancer Ther.
TALC: NINTEDANIB
- Version: 12-May-2016
Alternate Names:

NINTEDANIB Primary Drug Name

VARGATEF Drug Trade Name

BIBF 1120 Drug Synonym

Drug Info:

Publications:
TTD: Intedanib
- Version: 2020.06.01
Alternate Names:

D09HNV TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL502835
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ClearityFoundationClinicalTrial: NINTEDANIB
- Version: 15-June-2013
Alternate Names:

Drug Info:

Publications:

Trial Name	BIBF-1120,Vargatef
Novel drug target	Established target
Notes

Response Type	resistant
Indication/Tumor Type	urinary bladder cancer
Evidence Type	Actionable

Notes
Indication/Tumor Type	Advanced Solid Tumor
Response Type	decreased response

BIBF1120	Development Name
NINTEDANIB	Generic Name
VARGATEF	Trade Name

NINTEDANIB	Primary Drug Name
VARGATEF	Drug Trade Name
BIBF 1120	Drug Synonym

NINTEDANIB Drug Record

NINTEDANIB chembl:CHEMBL502835 ApprovedAntineoplastic

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes

PMIDs: None found

Sources: TALC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name BIBF-1120,Vargatef Novel drug target Established target Notes

PMIDs: 18559524 22238366 31016670

Sources: TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: ClearityFoundationClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Response Type resistant Indication/Tumor Type urinary bladder cancer Evidence Type Actionable

PMIDs: 22238366 18559524 31016670

Sources: TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial JAX-CKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes Indication/Tumor Type Advanced Solid Tumor Response Type decreased response

PMIDs: 18559524 22238366 31016670

Sources: TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial JAX-CKB TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes Trial Name BIBF-1120,Vargatef Novel drug target Established target

PMIDs: 31016670 18559524

Sources: TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes Trial Name BIBF-1120,Vargatef Novel drug target Established target

PMIDs: 31016670 18559524

Sources: TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes Trial Name BIBF-1120,Vargatef Novel drug target Established target

PMIDs: 18559524 31016670

Sources: TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes

PMIDs: 18559524 31016670

Sources: TALC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name BIBF-1120,Vargatef Novel drug target Established target Notes

PMIDs: 18559524 31016670

Sources: TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Novel drug target Established target Trial Name BIBF-1120,Vargatef Notes

PMIDs: 18559524 19522465 31016670

Sources: TALC DTC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes

PMIDs: 18559524 31016670

Sources: TALC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes

PMIDs: None found

Sources: TALC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes

PMIDs: 18559524 31016670

Sources: TALC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: None found

Sources: ClearityFoundationClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes

PMIDs: None found

Sources: TALC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: 18559524 31016670

Sources: TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes

PMIDs: None found

Sources: TALC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes

PMIDs: None found

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
None found

Sources:
TALC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name BIBF-1120,Vargatef

Novel drug target Established target

Notes

PMIDs:
18559524 22238366 31016670

Sources:
TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
ClearityFoundationClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Response Type resistant

Indication/Tumor Type urinary bladder cancer

Evidence Type Actionable

PMIDs:
22238366 18559524 31016670

Sources:
TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial JAX-CKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Indication/Tumor Type Advanced Solid Tumor

Response Type decreased response

PMIDs:
18559524 22238366 31016670

Sources:
TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial JAX-CKB TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Trial Name BIBF-1120,Vargatef

Novel drug target Established target

PMIDs:
31016670 18559524

Sources:
TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Trial Name BIBF-1120,Vargatef

Novel drug target Established target

PMIDs:
31016670 18559524

Sources:
TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Trial Name BIBF-1120,Vargatef

Novel drug target Established target

PMIDs:
18559524 31016670

Sources:
TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
18559524 31016670

Sources:
TALC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name BIBF-1120,Vargatef

Novel drug target Established target

Notes

PMIDs:
18559524 31016670

Sources:
TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name BIBF-1120,Vargatef

Notes

PMIDs:
18559524 19522465 31016670

Sources:
TALC DTC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
18559524 31016670

Sources:
TALC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
None found

Sources:
TALC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
18559524 31016670

Sources:
TALC

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
None found

Sources:
ClearityFoundationClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
None found

Sources:
TALC

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
18559524 31016670

Sources:
TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
None found

Sources:
TALC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
None found

Sources:
TALC

Interaction Types & Directionality:

n/a

PMIDs:
18559524

Sources:
DTC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
None found

Sources:
TALC